Skip to content
10-Q

Quarterly Report

LA JOLLA PHARMACEUTICAL CO

0001564590-20-052582

← back to feed
Filed
Nov 9, 2020 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2020 · Nov 3, 2020 27.38M sh
Current Liabilities Q3 2020 · Sep 30, 2020 $18.76M
Current Liabilities Q3 2020 · Dec 31, 2019 $24.59M
Total Liabilities Q3 2020 · Sep 30, 2020 $166.24M
Total Liabilities Q3 2020 · Dec 31, 2019 $188.24M
Current Assets Q3 2020 · Sep 30, 2020 $42.2M
Current Assets Q3 2020 · Dec 31, 2019 $97.46M
Total Assets Q3 2020 · Sep 30, 2020 $80.72M
Total Assets Q3 2020 · Dec 31, 2019 $132.25M
Cost Of Revenue Q3 2020 · Sep 30, 2020 $2.49M
Cost Of Revenue Q3 2020 · Sep 30, 2020 $4.01M
Cost Of Revenue Q3 2020 · Sep 30, 2019 $554K
Cost Of Revenue Q3 2020 · Sep 30, 2019 $1.61M
Cash And Equivalents Q3 2020 · Dec 31, 2019 $87.82M
Cash And Equivalents Q3 2020 · Sep 30, 2019 $104.77M
Capex Q3 2020 · Sep 30, 2019 $679K
Operating Cash Flow Q3 2020 · Sep 30, 2019 −$67.82M
Stockholders Equity Q3 2020 · Sep 30, 2019 −$35.17M
Stockholders Equity Q3 2020 · Jun 30, 2019 −$12.59M
Stockholders Equity Q3 2020 · Mar 31, 2019 $11.3M
Stockholders Equity Q3 2020 · Dec 31, 2018 $35.92M
Sga Expense Q3 2020 · Sep 30, 2019 $10.78M
Sga Expense Q3 2020 · Sep 30, 2019 $34.43M
Rd Expense Q3 2020 · Sep 30, 2019 $21.18M
Rd Expense Q3 2020 · Sep 30, 2019 $64.47M
Net Income Q3 2020 · Sep 30, 2019 −$29.17M
Net Income Q3 2020 · Sep 30, 2019 −$91.28M
Net Income Q3 2020 · Jun 30, 2019 −$30.42M
Net Income Q3 2020 · Mar 31, 2019 −$31.69M
Operating Income Q3 2020 · Sep 30, 2019 −$26.81M
Operating Income Q3 2020 · Sep 30, 2019 −$84.7M
Revenue Q3 2020 · Sep 30, 2019 $5.71M
Revenue Q3 2020 · Sep 30, 2019 $15.8M